Olema Pharmaceuticals, Inc. (OLMA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Olema Pharmaceuticals reported revenue of $0. Net income was -$162.5M, or -$1.87 per diluted share. Operating activities generated -$146.7M of cash, leaving -$146.9M of free cash flow. At fiscal year end, Olema Pharmaceuticals held $533.4M in total assets against $54.9M in total liabilities, including $48.3M of cash and equivalents.
Open the full interactive Olema Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Olema Pharmaceuticals Key Stats
| Share Price | $7.02 |
|---|---|
| Market Cap | $733.3M |
| 52-Week Range | $7.02 – $35.83 |
| Shares Outstanding | 104.5 million (basic, 2026 Q2) |
Olema Pharmaceuticals Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$71.5M | -$107.0M | -$105.0M | -$142.3M | -$178.7M |
| Pre-Tax Income | -$71.1M | -$104.8M | -$96.7M | -$129.5M | -$162.4M |
| Income Tax | — | $1,000 | $2,000 | $2,000 | $3,000 |
| Net Income | -$71.1M | -$104.8M | -$96.7M | -$129.5M | -$162.5M |
| Diluted EPS | -$1.80 | -$2.62 | -$2.14 | -$2.20 | -$1.87 |
Olema Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$42.2M | -$46.1M | -$53.1M | -$63.2M |
| Diluted EPS | -$0.49 | -$0.53 | -$0.52 | -$0.61 |
Olema Pharmaceuticals Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $13.8M | $23.7M | $68.5M | $139.5M | $48.3M |
| Current Assets | $290.7M | $208.9M | $266.5M | $438.5M | $515.5M |
| Total Assets | $295.9M | $215.6M | $276.9M | $451.0M | $533.4M |
| Current Liabilities | $9.0M | $16.5M | $21.6M | $41.8M | $51.8M |
| Total Long-Term Debt | — | — | — | — | $3.0M |
| Total Liabilities | $11.4M | $18.1M | $23.1M | $42.0M | $54.9M |
| Shareholders' Equity | $284.6M | $197.5M | $253.9M | $409.0M | $478.6M |
Olema Pharmaceuticals Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$50.7M | -$82.1M | -$83.7M | -$104.4M | -$146.7M |
| Cash From Investing | -$275.4M | $91.5M | -$4.9M | -$93.5M | -$155.8M |
| Cash From Financing | $1.4M | $476,000 | $133.4M | $268.8M | $211.3M |
| Free Cash Flow | -$52.3M | -$82.4M | -$84.1M | -$104.5M | -$146.9M |
Figures from Olema Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Olema Pharmaceuticals financials page for every line item.
Olema Pharmaceuticals Company Profile
| Ticker | OLMA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001750284 |
Frequently Asked Questions
What was Olema Pharmaceuticals' revenue in fiscal 2025?
Olema Pharmaceuticals (OLMA) reported revenue of $0 for fiscal 2025.
What is Olema Pharmaceuticals' annual revenue history?
Olema Pharmaceuticals' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Olema Pharmaceuticals' net income in fiscal 2025?
Olema Pharmaceuticals reported net income of -$162.5M for fiscal 2025.
What was Olema Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Olema Pharmaceuticals' diluted EPS was -$1.87 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Olema Pharmaceuticals generate in fiscal 2025?
Olema Pharmaceuticals generated -$146.9M of free cash flow in fiscal 2025.
What was Olema Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Olema Pharmaceuticals reported revenue of $0.
How much debt does Olema Pharmaceuticals have?
Olema Pharmaceuticals reported $3.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Olema Pharmaceuticals are outstanding?
Olema Pharmaceuticals reported a weighted average of 104.5 million basic shares outstanding in 2026 Q2.
What is Olema Pharmaceuticals' market cap?
Based on its latest closing price, Olema Pharmaceuticals (OLMA) has a market capitalization of about $733.3M.
When does Olema Pharmaceuticals' fiscal year end?
Olema Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Olema Pharmaceuticals headquartered?
Olema Pharmaceuticals lists its business address in San Francisco, California in its SEC filings.